In February, had the firm withdrawn an application for emergency-use authorisation of its vaccine in India, after failing to meet the drug regulatorâs demand for a local safety and immunogenicity study. Now, as per a new rule, the company is eligible to directly seek EUA from the Drugs Controller General of India.from Moneycontrol Business News https://ift.tt/3gpjbC7
No comments:
Post a Comment